Alnylam Pharmaceuticals
ALNY
#663
Rank
NZ$51.78 B
Marketcap
$401.51
Share price
-8.67%
Change (1 day)
41.52%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -NZ$0.3 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$2.09 Billion. In 2023 the company made an earning of -NZ$0.54 Billion, an increase over its 2022 earnings that were of -NZ$1.66 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -NZ$0.3 Billion-44.32%
2023 -NZ$0.54 Billion-67.84%
2022 -NZ$1.66 Billion36.93%
2021 -NZ$1.21 Billion-8.04%
2020 -NZ$1.32 Billion-15.66%
2019 -NZ$1.56 Billion12.23%
2018 -NZ$1.39 Billion62.91%
2017 -NZ$0.86 Billion17.78%
2016 -NZ$0.73 Billion43.44%
2015 -NZ$0.51 Billion60.69%
2014 -NZ$0.32 Billion98.2%
2013 -NZ$0.16 Billion
2011 -NZ$93.44 Million27.48%
2010 -NZ$73.3 Million-10.92%
2009 -NZ$82.28 Million95.77%
2008 -NZ$42.03 Million
2006 -NZ$67.33 Million-9.13%
2005 -NZ$74.1 Million34.74%
2004 -NZ$55 Million36.79%
2003 -NZ$40.21 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-NZ$0.9 Billion 181.30%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$8.47 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.10 B-133.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$0.42 Billion 30.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$59.66 Million-81.27%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$21.70 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$12.62 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$1.40 B-542.53%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel